Open Payments

BRIGHAM AND WOMENS HOSPITAL

Type
Teaching hospital
Where
BOSTON, MA
Medicare CCN
220110
Received
$57,962,347 in 1,871 records, 2024 ($8,122,911 general, $49,839,436 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment264$8,122,911
2024Research payment1,607$49,839,436

By company

CompanyRecordsAmountYears
Amgen Inc.24$5,545,9332024
E.R. Squibb & Sons, L.L.C.21$4,804,0782024
KOWA COMPANY, LTD.3$3,500,9902024
AstraZeneca UK Limited9$3,323,1542024
Novartis Pharmaceuticals Corporation19$3,313,4872024
Kowa Holdings America, Inc.250$3,268,6282024
PFIZER INC.45$2,750,6952024
Bayer Healthcare Pharmaceuticals Inc.6$2,533,7592024
Gilead Sciences, Inc.7$1,885,0432024
Genentech, Inc.34$1,677,0242024
Alexion Pharmaceuticals, Inc.11$1,513,2862024
Eli Lilly and Company15$1,433,1102024
Boehringer Ingelheim Pharmaceuticals, Inc.6$1,248,3492024
Alnylam Pharmaceuticals Inc.37$1,244,3322024
Novo Nordisk AS41$1,166,5802024
Janssen Research & Development, LLC15$1,061,0302024
Canon Medical Systems Corporation4$1,023,9772024
Boston Scientific Corporation71$997,6162024
Siemens Medical Solutions USA, Inc.25$992,6652024
InSightec,LTD10$903,4952024
Teva Pharmaceuticals USA, Inc.8$863,3582024
VERTEX PHARMACEUTICALS INCORPORATED8$833,8182024
Takeda Pharmaceuticals U.S.A., Inc.18$824,5252024
SANOFI US SERVICES INC.23$746,0852024
Daiichi Sankyo Inc.3$722,9932024
ModernaTX, Inc.34$706,5672024
Blueprint Medicines Corporation35$610,6732024
AstraZeneca Pharmaceuticals LP16$599,5792024
GENZYME CORPORATION8$514,9862024
Boehringer Ingelheim International GmbH1$496,5002024
Edwards Lifesciences Corporation48$486,5832024
Medtronic, Inc.23$460,1242024
Abbott Laboratories43$449,4752024
Eisai Inc.9$422,0692024
Konica Minolta Healthcare Americas, Inc3$372,2162024
Janssen Global Services, LLC2$300,0002024
Biogen, Inc.5$268,2592024
Genetix Biotherapeutics Inc32$210,7252024
Aadi Bioscience, Inc.3$182,2292024
Recor Medical Inc17$159,1062024
American Regent1$143,2862024
Endo USA, Inc.1$141,3882024
Medical Device Business Services, Inc.29$124,5172024
Arthrex, Inc.4$122,9692024
Lexicon Pharmaceuticals, Inc.7$119,2462024
ARGENX US, INC.107$118,2522024
ABBVIE INC.17$112,4232024
Regeneron Pharmaceuticals, Inc.396$111,4172024
BTG International Inc.2$110,2572024
Novartis Pharma AG3$98,3162024

By nature of payment

NatureRecordsAmount
Research payment1,607$49,839,436
Grant26$2,957,950
Compensation for services other than consulting, including serving as faculty or as a speaker at a v35$2,382,957
Royalty or License66$1,167,738
Charitable Contribution21$560,783
Space rental or facility fees (teaching hospital only)51$438,592
Consulting Fee18$367,847
Education17$117,301
Long term medical supply or device loan13$87,540
Debt forgiveness11$30,205
Gift6$11,993

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Siemens Medical Solutions USA, Inc.$145,463Research paymentIn-kind items and servicesEclipse Treatment Planning System for External Beam Radiation Therapy Device, OncologyCardiac RADIoablation versus repeat catheter Ablation: a pivotalrandomized clinical Trial Evaluating safety and efficacy2024
2024-12-31AngioDynamics, Inc.$60,000Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2024
2024-12-31KARL STORZ Endoscopy-America$35,662Research paymentIn-kind items and servicesTIPCAM1 Device, LAPAROSCOPYImage-guided Lymphadenectomy in AMIGO (Advanced Multimodality Image-Guided Operating) (Augmented Reality Surgical Naviga2024
2024-12-31ENDOTRONIX, INC.$27,251Research paymentCash or cash equivalentCORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILUREPROACTIVE-HF2024
2024-12-31AstraZeneca Pharmaceuticals LP$24,081Research paymentIn-kind items and servicesBREZTRI Drug, RespiratoryA Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi2024
2024-12-31KARL STORZ Endoscopy-America$15,431Research paymentIn-kind items and servicesTIPCAM1 Device, LAPAROSCOPYImage-guided Lymphadenectomy in AMIGO (Advanced Multimodality Image-Guided Operating) (Augmented Reality Surgical Naviga2024
2024-12-31Haemonetics Corporation$9,047Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHROMBOELASTOGRAPHIC PROFILES IN POST-PARTUM HEMORRHAGE2024
2024-12-31Cambridge Interventional LLC$6,000Long term medical supply or device loanIn-kind items and servicesCRF Device, RFA2024
2024-12-31Intuitive Surgical, Inc.$5,000EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Intuitive Surgical, Inc.$4,000Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Abbott Laboratories$2,625Research paymentIn-kind items and servicesARCHITECT Device, CORE DIAGNOSTICSEvaluation of Cardiovascular Biomarkers in Patients with Type 2 Diabetes Mellitus at Risk for or with Estiblished Athero2024
2024-12-31AstraZeneca Pharmaceuticals LP$2,189Research paymentIn-kind items and servicesTEZSPIRE Biological, RespiratoryA Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab2024
2024-12-31AstraZeneca Pharmaceuticals LP$1,473Research paymentIn-kind items and servicesFARXIGA Drug, Cardiovascular and Metabolism";Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Ev2024
2024-12-31PFIZER INC.$1,000Research paymentCash or cash equivalentA PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF 2024
2024-12-31ABBVIE INC.$749Research paymentIn-kind items and servicesM16-077 Elezanumab Ph 2a POC SCI ELASCI2024
2024-12-31Abbott Laboratories$700Research paymentIn-kind items and servicesARCHITECT Device, CORE DIAGNOSTICSPRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study2024
2024-12-31AstraZeneca Pharmaceuticals LP$381Research paymentIn-kind items and servicesLOKELMA Drug, Cardiovascular and MetabolismTA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descrip2024
2024-12-31Stryker Corporation$343Long term medical supply or device loanIn-kind items and servicesPRIME SERIES Device, PATIENT HANDLING - PH2024
2024-12-31Masimo Corporation$342Long term medical supply or device loanCash or cash equivalentLiDCO Device, Devices2024
2024-12-31Masimo Corporation$342Long term medical supply or device loanCash or cash equivalentLiDCO Device, Devices2024
2024-12-31Masimo Corporation$342Long term medical supply or device loanCash or cash equivalentLiDCO Device, Devices2024
2024-12-31Masimo Corporation$342Long term medical supply or device loanCash or cash equivalentLiDCO Device, Devices2024
2024-12-31Masimo Corporation$342Long term medical supply or device loanCash or cash equivalentLiDCO Device, Devices2024
2024-12-31Atos Medical Inc$93Debt forgiveness (3 payments)Cash or cash equivalentProvox Life Home HME Device, Tracheostomy2024
2024-12-30InSightec,LTD$865,678Royalty or LicenseCash or cash equivalentEXABLATE Device, NEUROLOGY2024
2024-12-30PFIZER INC.$508,271Research paymentCash or cash equivalentA PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF 2024
2024-12-30ModernaTX, Inc.$1,625Research paymentCash or cash equivalentA Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Va2024
2024-12-30Cleerly, Inc.$1,580Research paymentCash or cash equivalentCleerly Ischemia Device, Cardiology/Vascular DiseasesConfirm22024
2024-12-27Kowa Holdings America, Inc.$524Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-26Ferring Pharmaceuticals AS$17,787Research paymentCash or cash equivalentREBYOTA Biological, GASTROENTEROLOGYA Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcer2024
2024-12-26Ferring Pharmaceuticals AS$2,700Research paymentCash or cash equivalentREBYOTA Biological, GASTROENTEROLOGYA Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcer2024
2024-12-26Abbott Laboratories$2,000Consulting FeeCash or cash equivalentXIENCE SKYPOINT Device, Vascular2024
2024-12-26Regeneron Pharmaceuticals, Inc.$591Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$591Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$50Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$45Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$45Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$45Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$45Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$32Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$32Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-26Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-25Canon Medical Systems Corporation$169,745Research paymentCash or cash equivalent2024
2024-12-24Kowa Holdings America, Inc.$4,903Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-24InSightec,LTD$1,111Research paymentCash or cash equivalentExablate Device, NEUROLOGYPD0062024
2024-12-24Kowa Holdings America, Inc.$572Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-23SANOFI US SERVICES INC.$82,818Research paymentCash or cash equivalent2024
2024-12-23ROCHE DIAGNOSTICS INTERNATIONAL LTD$43,960Research paymentCash or cash equivalent DeviceSUB-0017162024
2024-12-23Roche Diagnostics Corporation$21,753Research paymentCash or cash equivalent Device, NoneRD007294: The BREATHE Study: Benefits of Respiratory Evaluation Approaches to Testing on Health Economics2024
2024-12-23Medical Device Business Services, Inc.$4,700Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-23Janssen Research & Development, LLC$2,466Research paymentCash or cash equivalentSTELARA Biological, ImmunologyProspective evaluation of ustekinumab dose intesification in inflammatory bowel diseases2024
2024-12-23Siemens Medical Solutions USA, Inc.$264Royalty or LicenseCash or cash equivalent2024
2024-12-20Konica Minolta Healthcare Americas, Inc$90,000Research paymentCash or cash equivalentClinical Research Support2024
2024-12-20Apellis Pharmaceuticals, Inc.$84,702Research paymentCash or cash equivalent2024
2024-12-20E.R. Squibb & Sons, L.L.C.$36,712Research paymentCash or cash equivalentZEPOSIA Drug, NeuroscienceCharacterization of scRNAseq profiles associated with ozanimod treatment and age in MS patients2024
2024-12-20Blueprint Medicines Corporation$9,179Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis2024
2024-12-20Recor Medical Inc$8,308Research paymentCash or cash equivalentPARADISE RENAL DENERVATION SYSTEM Device, NephrologyUS GPS2024
2024-12-20Arrow International, Inc.$2,500Research paymentCash or cash equivalentGUIDELINER Device, INTERVENTIONAL ACCESS"A Real World Multi-Center Retrospective Chart Review Study of GuideLiner Coast Catheters"2024
2024-12-20Novo Nordisk AS$869Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-12-20Novo Nordisk AS$778Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522024
2024-12-20Recor Medical Inc$260Research paymentCash or cash equivalentPARADISE RENAL DENERVATION SYSTEM Device, NephrologyRADIANCE II2024
2024-12-19Genentech, Inc.$60,000Charitable ContributionCash or cash equivalent2024
2024-12-19Novartis Pharmaceuticals Corporation$15,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-19Recor Medical Inc$8,308Research paymentCash or cash equivalentPARADISE RENAL DENERVATION SYSTEM Device, NephrologyUS GPS2024
2024-12-19Medical Device Business Services, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-19Medical Device Business Services, Inc.$400Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-18GE HEALTHCARE$8,387Research paymentCash or cash equivalentDEFINE/DEVELOP LEARNING PLATFORM2024
2024-12-18Becton, Dickinson and Company$6,683Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$5,574Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$2,907Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$1,189Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$476Royalty or LicenseCash or cash equivalent2024
2024-12-18ARGENX US, INC.$300Research paymentCash or cash equivalentVYVGART Drug, ImmunologyA Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of 2024
2024-12-18Becton, Dickinson and Company$159Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$133Royalty or LicenseCash or cash equivalent2024
2024-12-18Becton, Dickinson and Company$18Royalty or LicenseCash or cash equivalent2024
2024-12-17Life Technologies Corporation$54,302Royalty or License (26 payments)Cash or cash equivalent2024
2024-12-17Kowa Holdings America, Inc.$9,260Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-17HARMONY BIOSCIENCES LLC$5,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentWAKIX Drug, Narcoplepsy2024
2024-12-17Boston Scientific Corporation$3,684Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICVITALYST Early Feasibility Study2024
2024-12-17Boston Scientific Corporation$2,254Research paymentCash or cash equivalentPrecision Device, Precision_NMDRELIEF2024
2024-12-17Kowa Holdings America, Inc.$1,099Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-16Teva Pharmaceuticals USA, Inc.$29,326Research paymentCash or cash equivalentAJOVY Biological, Central Nervous SystemParallel-Group Study to Evaluate the Efficacy and Safety of Fremanezumab (675 mg quarterly) in Female Patients aged 18-42024
2024-12-16Edwards Lifesciences Corporation$17,316Research paymentCash or cash equivalentALLIANCE 2021-052024
2024-12-16SANOFI US SERVICES INC.$13,848Research paymentCash or cash equivalentA Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and T2024
2024-12-16Smith+Nephew, Inc.$4,332Research paymentCash or cash equivalentA Post Approval Multicenter Open-label Randomized Controlled Trial of Agili-C vs. Surgical Standard of Care (SSOC) for t2024
2024-12-16Kowa Holdings America, Inc.$2,881Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-13Genentech, Inc.$25,000Charitable ContributionCash or cash equivalent2024
2024-12-13Teleflex LLC$8,580Research paymentCash or cash equivalentBarrigel Pivotal Trial2024
2024-12-13Kowa Holdings America, Inc.$7,889Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-13Kowa Holdings America, Inc.$7,300Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-13Teleflex LLC$6,144Research paymentCash or cash equivalentBarrigel Pivotal Trial2024
2024-12-13VERTEX PHARMACEUTICALS INCORPORATED$2,850Research paymentCash or cash equivalentA Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine2024
2024-12-13Kowa Holdings America, Inc.$1,911Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-13Teleflex LLC$1,900Research paymentCash or cash equivalentBarrigel Pivotal Trial2024
2024-12-13Teleflex LLC$1,170Research paymentCash or cash equivalentBarrigel Pivotal Trial2024
2024-12-13Stryker Corporation$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentSONOPET IQ Device, NEURO SPINE ENT2024
2024-12-13Lexicon Pharmaceuticals, Inc.$627Research paymentCash or cash equivalentLX92112024
2024-12-13Regeneron Pharmaceuticals, Inc.$591Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$218Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$100Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$37Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$33Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$28Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-13Regeneron Pharmaceuticals, Inc.$26Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA)2024
2024-12-12Edwards Lifesciences Corporation$8,935Research paymentCash or cash equivalentPartner3 2015-082024
2024-12-12Edwards Lifesciences Corporation$6,482Research paymentCash or cash equivalentPartner3 2015-082024
2024-12-12Medtronic, Inc.$875Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-11Mallinckrodt Hospital Products Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentACTHAR Biological, IMMUNOLOGY2024
2024-12-10Gilead Sciences, Inc.$294,715Research paymentCash or cash equivalentStigma among primary care providers: characterizing attitudes and behaviors in the care of people with chronic hepatitis2024
2024-12-10Siemens Medical Solutions USA, Inc.$52,953Research paymentCash or cash equivalentVarian Ethos Treatment Planning Device, OncologyDaily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer with Urethral Sparing: A Prospective Trial Using 2024
2024-12-10E.R. Squibb & Sons, L.L.C.$45,374Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularTrends in Clinical Prescribing Patterns for Apixaban in Patients with Morbid Obesity and Chronic Kidney Disease2024
2024-12-10Boston Scientific Corporation$4,306Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMAVANT GUARD2024
2024-12-10Kowa Holdings America, Inc.$3,020Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-10Acessa Health Inc.$2,827Research paymentCash or cash equivalentACESSA PROVU SYSTEM Device, SurgicalTRUST USA CP-00-00252024
2024-12-10Boston Scientific Corporation$2,587Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2024
2024-12-10Kowa Holdings America, Inc.$596Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-10Kowa Holdings America, Inc.$162Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-10Kowa Holdings America, Inc.$99Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-09PFIZER INC.$519,588Research paymentCash or cash equivalentA PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF 2024
2024-12-09Medtronic, Inc.$1,000Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2024
2024-12-06Boehringer Ingelheim Pharmaceuticals, Inc.$46,448Research paymentCash or cash equivalentBI 1015550 - Ph3 Open Label Extension2024
2024-12-06Blueprint Medicines Corporation$17,300Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis2024
2024-12-06Medtronic, Inc.$5,848Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-06Medtronic, Inc.$2,450Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-06Medtronic, Inc.$337Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-06Medtronic, Inc.$119Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-05Alnylam Pharmaceuticals Inc.$18,030Research paymentCash or cash equivalentAMVUTTRA Drug, Genetic DiseaseHELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy2024
2024-12-05Boston Scientific Corporation$1,875Consulting FeeCash or cash equivalent Device, Clinical Trial Product_PI2024
2024-12-05Alnylam Pharmaceuticals Inc.$520Research paymentCash or cash equivalentAMVUTTRA Drug, Genetic DiseaseHELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy2024
2024-12-05Kowa Holdings America, Inc.$496Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-05Kowa Holdings America, Inc.$342Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-05Alnylam Pharmaceuticals Inc.$260Research paymentCash or cash equivalentAMVUTTRA Drug, Genetic DiseaseHELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy2024
2024-12-04Kowa Holdings America, Inc.$136,552Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-04Kowa Holdings America, Inc.$34,344Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-04Kowa Holdings America, Inc.$32,761Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-04Kowa Holdings America, Inc.$4,104Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-04Kowa Holdings America, Inc.$3,162Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-04Genentech, Inc.$2,365Research paymentCash or cash equivalentRVT-3101-201 (TAHOE)2024
2024-12-04Kowa Holdings America, Inc.$680Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-03Amgen Inc.$59,266Research paymentCash or cash equivalentPh3 ASCVD Outcomes Trial2024
2024-12-03Amgen Inc.$1,080Research paymentIn-kind items and servicesRW Treatment Patterns; Healthcare Resource Utilization and Cost of SLE2024
2024-12-03Indivior Inc.$1,000Research paymentCash or cash equivalentSUBLOCADE Drug, OUDA RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS 2024
2024-12-03Indivior Inc.$1,000Research paymentCash or cash equivalentSUBLOCADE Drug, OUDA RANDOMISED, DOUBLE-BLIND STUDY COMPARING 2 MAINTENANCE DOSING REGIMENS OF BUPRENORPHINE EXTENDED-RELEASE SUBCUTANEOUS 2024
2024-12-02Takeda Pharmaceuticals U.S.A., Inc.$95,281Research paymentCash or cash equivalentPOST-OP RECOVERY - OREXIN2024
2024-12-02Kowa Holdings America, Inc.$75,148Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-02Takeda Pharmaceuticals U.S.A., Inc.$1,960Research paymentCash or cash equivalentPOST-OP RECOVERY - OREXIN2024
2024-12-02Kowa Holdings America, Inc.$750Research paymentCash or cash equivalentBAWH_KSI2024
2024-12-02Takeda Pharmaceuticals U.S.A., Inc.$486Research paymentCash or cash equivalentPOST-OP RECOVERY - OREXIN2024
2024-12-02ARGENX US, INC.$1Research paymentCash or cash equivalentVYVGART Drug, ImmunologyQuincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efg2024
2024-12-02ARGENX US, INC.$0Research paymentCash or cash equivalentVYVGART Drug, ImmunologyQuincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efg2024
2024-12-01ARGENX US, INC.$70Research paymentCash or cash equivalentVYVGART HYTRULO Drug, NeurologyA Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless 2024
2024-11-29BTG International Inc.$21,157Research paymentCash or cash equivalentVORAXAZE Drug, Toxicity Antidote (Methotrexate Toxicity)Rechallenge with Methotrexate after Administration of Glucarpidase for Methotrexate-Associated Acute Kidney Injury2024
2024-11-27Edwards Lifesciences Corporation$4,549Research paymentCash or cash equivalentTRISCEND II Pivotal (2020-05)2024
2024-11-27Ferring Pharmaceuticals AS$675Research paymentCash or cash equivalentREBYOTA Biological, GASTROENTEROLOGYREBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational2024
2024-11-26Amgen Inc.$18,425Research paymentCash or cash equivalentTAVNEOS Drug, InflammationPh4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_1682024
2024-11-26Kowa Holdings America, Inc.$11,302Research paymentCash or cash equivalentBAWH_KSI2024
2024-11-26Kowa Holdings America, Inc.$10,474Research paymentCash or cash equivalentBAWH_KSI2024
2024-11-26Kowa Holdings America, Inc.$4,903Research paymentCash or cash equivalentBAWH_KSI2024

The latest 200 records of 1,871.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.